GlassScriptPhysician profile
Ryan H Moy
NPI 1164816005
$17,279.93
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 84% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $172 · 2024: $2,293 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $2,391 · Travel and Lodging: $1,067 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.09 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,622.54 |
| Food and Beverage | $2,390.58 |
| Travel and Lodging | $1,067.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.09 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,927.34 | 2022-2025 | Opdivo |
| Gilead Sciences, INC. | $2,180.00 | 2025 | |
| Beone Medicines USA, INC. | $2,054.59 | 2025 | Tevimbra |
| Novartis Pharmaceuticals Corporation | $1,563.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,034.85 | 2022-2025 | Imfinzi |
| Trisalus Life Sciences, INC. | $978.65 | 2024 | Trinav Infusion System |
| Amgen INC. | $710.87 | 2025 | |
| Becton, Dickinson and Company | $516.67 | 2024 | |
| Phathom Pharmaceuticals, INC. | $123.66 | 2024 | Voquezna |
| Exelixis INC. | $114.21 | 2025 | |
| Merck Sharp & Dohme LLC | $54.81 | 2023-2024 | Keytruda |
| Daiichi Sankyo INC. | $20.49 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Moy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.